Urethane

DB04827

small molecule approved withdrawn

Deskripsi

Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

Struktur Molekul 2D

Berat 89.0932
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

688 Data
Buprenorphine Urethane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Hydrocodone Urethane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Magnesium sulfate The therapeutic efficacy of Urethane can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Urethane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Urethane may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Mirtazapine Urethane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Orphenadrine Urethane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Urethane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Pramipexole Urethane may increase the sedative activities of Pramipexole.
Ropinirole Urethane may increase the sedative activities of Ropinirole.
Rotigotine Urethane may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Urethane.
Sodium oxybate Urethane may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Urethane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Thalidomide Urethane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Urethane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Urethane.
Ethanol Urethane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Urethane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Fluvoxamine The risk or severity of adverse effects can be increased when Urethane is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Urethane is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Urethane is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Urethane is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Urethane is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Urethane is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Urethane is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Urethane is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Urethane is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Urethane is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Urethane is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Urethane is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Urethane is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Urethane is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Urethane is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Urethane is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Urethane is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Urethane.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Urethane.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Urethane.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Urethane.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Urethane.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Urethane.
Cocaine The risk or severity of methemoglobinemia can be increased when Urethane is combined with Cocaine.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Urethane.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Urethane.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Urethane.
Pizotifen The risk or severity of CNS depression can be increased when Urethane is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Urethane is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Urethane is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Urethane.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Urethane.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Urethane.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Urethane.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Urethane.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Urethane.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Urethane.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Urethane.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Urethane.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Urethane.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Urethane.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Urethane.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Urethane.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Urethane.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Urethane.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Urethane.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Urethane.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Urethane.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Urethane.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Urethane.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Urethane.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Urethane.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Urethane.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Urethane.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Urethane.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Urethane.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Urethane.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Urethane.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Urethane.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Urethane.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Urethane.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Urethane.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Urethane.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Urethane.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Urethane.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Urethane.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Urethane.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Urethane.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Urethane.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Urethane.
Sulpiride The risk or severity of CNS depression can be increased when Sulpiride is combined with Urethane.
Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Urethane.

Referensi & Sumber

Synthesis reference: Norton A. Cashen, "Method of producing anhydrous crystalline reaction products of formaldehyde and methyl-, ethyl carbamate." U.S. Patent US4002668, issued July, 1973.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul